Skip to main content
MRK logo

Merck & Co., Inc. (MRK) Stock: Price, Forecast & Analyst Target

Merck & Co., Inc. (MRK) — MoonshotScore 69/100 (Strong band), calculated Nov 18, 2026. Price $137.78 (-3.90%), as of the Nov 18, 2026 trading session; market cap $340B. Expected results Feb 2, 2027.

Educational signal · not a buy or sell recommendation · How to read this

$137.78 −$5.59 (-3.90%) Market Cap $340B

Merck & Co., Inc. · MRK · NYSE · Healthcare · Drug Manufacturers - General

Research dated 2026-09-12: Merck sells human medicines and vaccines through pharmaceutical channels, while its animal-health arm supplies veterinary drugs, vaccines and digital identification and monitoring tools. The decisive issue is whether cash-generative operations can absorb the recent surge in research expense and restore reported profitability without revenue losing momentum.

Price as of Nov 18, 2026

Key Statistics

69 of 100

MoonshotScore v2 · Merck & Co. (MRK)

Strong
Business Quality Elite (84)
Financial Safety Strained (29)
Valuation Full (43)
Growth Durability Flat (54)
Momentum Surging (89)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a strained balance sheet and a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Strained; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 0 of the last 4 reports
  • expected results Feb 2, 2027
  • Altman Z 3.87 · Piotroski F 5

Holding back: balance-sheet strain

Helping: business quality, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for MRK (57 recorded, newest six shown)
RecordedScoreBand
75Strong
73Strong
72Strong
72Strong
69Strong
69Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$137.78
Change on the day-3.90%
52-week range$92.11–$156.92
Market capitalisation$340B—
Price / earnings (trailing)144.82
Shares traded on the day9.69M
Beta (volatility vs the S&P 500)0.22

Why Merck & Co. scores 69

Dr. Mira Sol, the Stock Expert AI TV data character
Momentum carries the score; Financial Safety is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
69Strong
  • Business Quality84
  • Financial Safety29
  • Valuation43
  • Growth Durability54
  • Momentum89

Share price, last 12 months +71.4%

$86.75 $148.71

What the price assumes

10.1% a year of free-cash-flow growth for ten years is what a $366.89B market value ( snapshot) asks for.

  • Price implies, next ten years10.1%
  • Free cash flow, last 5 years16.2%
  • Revenue, last 5 years9.4%
  • Analysts' revenue path, 2026–20302.7%

The growth the price implies sits inside what the business has recently delivered, so the valuation leans on that record continuing. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $14.75B. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 11 of the last 12 reports (2024–2026); the stock still fell the next session after 4 of those beats. Average first-session move: 4.4% either way.

  1. +4.7%Feb ’24
  2. +3.3%Apr ’24
  3. -11.5%Jul ’24
  4. -2.8%Oct ’24
  5. -10.1%Feb ’25
  6. +5.1%Apr ’25
  7. -2.7%Jul ’25
  8. -0.7%Oct ’25
  9. +4.4%Feb ’26
  10. +1.1%Apr ’26
  11. +0.4%Aug ’26
  12. +6.1%Oct ’26
Next-session move EPS beat (11) EPS miss (1)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatBeat+6.1%+4.3%
BeatBeat+0.4%+2.1%
BeatBeat+1.1%+1.2%
BeatBeat+4.4%+3.3%
BeatBeat-0.7%-0.9%
BeatIn line-2.7%-3.9%
BeatBeat+5.1%+5.8%
MissIn line-10.1%-13.3%
BeatBeat-2.8%-3.5%
BeatBeat-11.5%-13.0%
BeatBeat+3.3%+1.0%
BeatIn line+4.7%+4.8%

Beats have usually been rewarded — 7 of 11 drew a higher close the next session.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “sac tmt”, “keytruda loe”, “heart failure”, “term growth” — none of them came up in Q2 FY2026.
  • Getting louder: “long term” (1 → 9 mentions), “lung cancer” (2 → 9 mentions), “cell lung” (2 → 8 mentions).
  • Gone quiet: “forward-looking statements”, “investor event”, “oral once-weekly”, “rheumatoid arthritis” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.9 to 2.7 per 1,000 words, and confident words such as “record” and “strong” rose from 4.4 to 5.5.

Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.

Our track record on this stock

Since the score went from 74 to 69 while the share price moved -8.5% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Strong band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 68% of 38 rate it a buy; the average target sits +16.5% from the price of $137.78.
  • Last 90 days: 2 upgrades and 1 downgrade among 24 rating actions.
  • Our signals: Strong band; strongest pillar Momentum (89), weakest Financial Safety (29).

Here we and the crowd agree.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $85, high $153, latest $138. $153 $85 high $153 Oct 17, 2025 Nov 18, 2026 · $138 $85Oct 17, 2025$86Oct 31, 2025$93Nov 14, 2025$105Nov 28, 2025$100Dec 12, 2025$107Dec 26, 2025$111Jan 9, 2026$108Jan 23, 2026$122Feb 6, 2026$122Feb 20, 2026$116Mar 6, 2026$114Mar 20, 2026$121Apr 2, 2026$119Apr 17, 2026$112May 1, 2026$111May 15, 2026$119May 29, 2026$119Jun 12, 2026$129Jun 26, 2026$124Jul 10, 2026$131Jul 24, 2026$129Aug 7, 2026$153Aug 21, 2026$150Sep 4, 2026$147Sep 18, 2026$144Oct 2, 2026$146Oct 16, 2026$150Oct 30, 2026$148Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Merck & Co. (MRK): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Negative
ROE Neutral
Gross Margin Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Merck & Co. (MRK), and what does it report?

Short answer · as of

Merck commercializes therapies across oncology, hospital care, immunology, neuroscience, virology, cardiovascular disease and diabetes, alongside preventive vaccines.

Demand reaches Merck through wholesalers, pharmacies, hospitals, government agencies, managed-care organizations, physicians and other institutional customers.

Pharmaceuticals provide the overwhelming share of reported sales. Animal Health is smaller but economically distinct, tying Merck to veterinary care, livestock production and animal monitoring rather than making the company solely dependent on human medicines.

2 · Latest results

What do the latest results show for Merck & Co. (MRK)?

Revenue remained near its elevated base and improved in the latest reported period, while gross profit eased and operating and net results stayed negative. Losses narrowed from the preceding period, but research expense remained far above its earlier quarterly run rate; unusually heavy research spending, rather than collapsing sales, is the defining feature of the recent accounts.

The earnings-history measure was less negative than expected, while revenue also cleared the estimate. Management separately attributed its elevated full-year tax expectation to the nondeductible onetime Terns charge; that comment explains the tax outlook, not the research-spending surge.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$17.28B$5.79B$2.32 (diluted)
Q4 FY2025$16.40B$2.96B$1.19 (diluted)
Q1 FY2026$16.29B-$4.24B-$1.72 (diluted)
Q2 FY2026$16.61B-$1.33B-$0.54 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Merck & Co. (MRK)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow remained positive throughout the displayed series and strengthened in the latest period, comfortably covering capital expenditure even while accounting results showed losses. Short-term liquidity ratios sit above parity, but total debt greatly exceeds liquid holdings, making Merck cash-generative rather than net-cash funded.

Cash and short-term investments have declined across the reported window despite a recent rebound. Pharmaceutical concentration compounds that balance-sheet pressure: failure of the human medicines and vaccines portfolio to offset heavy research expense would squeeze earnings and reduce room to rebuild liquidity while carrying the debt load.

Data-derived red flags

  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Rich valuation — a P/E of 144.82 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Merck & Co. (MRK)?

Short answer · as of

The next earnings report is expected on Feb 2, 2027.

The next report should be read for a return to operating and net profitability, movement in research expense, and whether revenue extends its latest improvement. Cash conversion deserves equal attention because operating cash strengthened while reported earnings remained negative.

Watch whether liquid balances continue recovering and whether management preserves its announced product-launch timetable. Longer-range estimates anticipate revenue expansion before becoming comparatively flatter, so the useful test is execution against that path rather than the consensus label itself.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Merck & Co. compare with its peers?

Short answer

Merck & Co.'s score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Compared with a pure human-pharmaceutical manufacturer, Merck contains a commercially meaningful animal-health franchise. That operation sells veterinary medicines and vaccines to veterinarians and livestock producers, then extends the relationship through identification, traceability and continuous-monitoring products.

Pharmaceuticals still dwarf Animal Health in reported sales. The animal franchise diversifies customers and demand channels, but Merck’s consolidated economics remain dominated by commercialization and research in human health.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Same industry, near in market value$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Named competitor$39.43 Nov 18, 2026$174B87 5-pillar Nov 18, 2026
Sanofi (SNY) Same industry, near in market value$47.12 Nov 18, 2026$113B87 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Named competitor$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Same industry, near in market value$59.56 Nov 18, 2026$122B85 5-pillar Nov 18, 2026
Amgen Inc. (AMGN) Named competitor$443.89 Nov 18, 2026$240B84 5-pillar Nov 18, 2026
AbbVie Inc. (ABBV) Same industry, near in market value$286.01 Nov 18, 2026$506B83 5-pillar Nov 18, 2026
Johnson & Johnson (JNJ) Same industry, near in market value$272.70 Nov 18, 2026$656B83 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
GSK plc (GSK) Same industry, near in market value$48.58 Nov 18, 2026$97.4B77 5-pillar Nov 18, 2026
Gilead Sciences, Inc. (GILD) Same industry, near in market value$168.98 Nov 18, 2026$210B72 5-pillar Nov 18, 2026
Thermo Fisher Scientific Inc. (TMO) Named competitor$692.74 Nov 18, 2026$257B70 5-pillar Nov 18, 2026
Merck & Co. (MRK) — this page$137.78$340B69

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$105.00 – $180.00
Consensus target
$159.45
Median target
$165.00

Consensus record · Captured .

Measured against a quoted price of $137.78 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
51
Identified insiders
18
Purchases
0
Sales
14
Other transactions
37

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held MRK in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported MRK in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Merck & Co. (MRK)?

Read these with our analysis →

MRK Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How important is Merck Animal Health beside its pharmaceutical business?

Animal Health is a substantial standalone operation, but pharmaceuticals contribute the overwhelming majority of segment revenue. Its value is diversification into veterinary and livestock demand, not equal balance with human health.

Why did Merck post losses while revenue stayed resilient?

The losses coincided with research expense rising far above its earlier quarterly pattern. Revenue remained resilient and the latest loss narrowed, so the recent deterioration is concentrated in reported costs rather than a broad sales collapse.

What does Merck sell to veterinarians and livestock producers?

Merck supplies veterinary medicines and vaccines, along with tools for animal identification, traceability and continuous monitoring. This creates a demand stream linked to animal care and livestock management rather than human prescribing.

How does the Terns charge affect Merck’s outlook?

Management says the nondeductible onetime Terns charge raises the expected full-year tax rate. It explains the tax guidance but should not be treated as an explanation for the operating loss or research-spending surge.

What is the MRK stock price today?

The last price recorded for Merck & Co., Inc. (MRK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the MRK price target?

The analyst consensus price target for Merck & Co., Inc. (MRK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions)
  • 1. What is Merck & Co. (MRK), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment
  • 2. What do the latest results show for Merck & Co. (MRK)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Recent SEC filings; Most recent periodic reports
  • 3. What are the financial strengths and risks for Merck & Co. (MRK)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Trailing twelve-month ratio set; Revenue by segment
  • 4. What should you watch next at Merck & Co. (MRK)?: Next earnings report; Analyst revenue and earnings estimates (average); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters
  • 5. How does Merck & Co. compare with its peers?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: How important is Merck Animal Health beside its pharmaceutical business?: Revenue by segment; Business description
  • FAQ: Why did Merck post losses while revenue stayed resilient?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters
  • FAQ: What does Merck sell to veterinarians and livestock producers?: Business description; Revenue by segment
  • FAQ: How does the Terns charge affect Merck’s outlook?: Management outlook — dated call excerpts; Quarterly income statement (USD thousands)
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold MRK

Funds in our ETF coverage that list MRK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Evolved U.S. Innovative Healthcare ETF (IEIH)5.77%
PBPH ETF4.89%
Brookstone Value Stock ETF (BAMV)4.65%
iShares Genomics Immunology and Healthcare ETF (IDNA)4.22%
VHT ETF4.19%
WisdomTree U.S. High Dividend Fund (DHS)4.10%
ProShares - Ultra Health Care (RXL)3.76%
IXJ ETF3.71%
Genter Capital Dividend Income ETF (GEND)3.50%
American Century STOXX U.S. Quality Value ETF (VALQ)2.88%